Alzamend Neuro

Alzamend announced that an abstract on its lithium formulation AL001 has been accepted for a poster presentation at Neuroscience 2026 in Washington, D.C. The presentation will report 7T resting-state fMRI results from the completed randomized phase 1/2a study, which analyzed treatment-related changes in brain network connectivity in healthy subjects. The study used a crossover design with AL001 and lithium carbonate; AL001 is an ionic cocrystal formulation intended to deliver lithium to the brain with lower systemic exposure. » More on de.investing.com

AL001 achieved FDA‑compliant bioequivalence to standard lithium carbonate in a Phase 2 study at Massachusetts General Hospital (101% AUC, 97% Cmax) and showed numerically higher lithium levels in 26 brain regions, with about 7.8% higher total brain exposure and a faster time to peak. The randomized crossover study in healthy volunteers included 12 participants and 14‑day dosing cycles. Alzamend has started a second Phase 2 study in bipolar disorder and plans three additional patient studies for HSD, PTSD and Alzheimer’s disease in the second half of 2026, subject to financing; the company currently has negative free cash flow and a small market capitalization. » More on de.investing.com